Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.73 million versus the consensus estimate of $1.77 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.